Scinai Immunotherapeutics' CDMO Unit And Ayana Pharma Signed A Five-Year Master Service Agreement to Provide Drug Development and cGMP Manufacturing Services
Portfolio Pulse from Benzinga Newsdesk
Scinai Immunotherapeutics' CDMO unit has entered into a five-year Master Service Agreement (MSA) with Ayana Pharma to provide drug development and cGMP manufacturing services. This includes aseptic filling, quality assurance, and encapsulating drug substances into Ayana's proprietary liposomal drug delivery system.

April 08, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scinai Immunotherapeutics' partnership with Ayana Pharma for drug development and manufacturing services could enhance its revenue streams and market position.
The agreement with Ayana Pharma is likely to provide Scinai Immunotherapeutics with a steady revenue stream over the next five years, enhancing its financial stability and potentially its stock price. The partnership also positions Scinai as a key player in the drug development and manufacturing sector, which could attract further business and partnerships.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90